1,795,347 Shares in Organogenesis $ORGO Acquired by Driehaus Capital Management LLC

Key Points

• Driehaus Capital Management LLC acquired 1,795,347 shares of Organogenesis valued at approximately $7,756,000, representing about 1.42% ownership after the latest reporting period.
• Organogenesis reported a quarterly loss of ($0.09) EPS, missing analysts' expectations, with revenue of $101.01 million compared to the projected $104.75 million.
• Analysts have a consensus rating of "Moderate Buy" for Organogenesis, with an average price target of $7.50, and Cantor Fitzgerald recently raised their price objective for the stock to $9.00.

Driehaus Capital Management LLC bought a new position in shares of Organogenesis (NASDAQ:ORGO - Free Report) during the 1st quarter, according to its most recent disclosure with the SEC. The fund bought 1,795,347 shares of the company's stock, valued at approximately $7,756,000. Driehaus Capital Management LLC owned 1.42% of Organogenesis at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ORGO. Wells Fargo & Company MN boosted its stake in shares of Organogenesis by 29.6% in the 4th quarter. Wells Fargo & Company MN now owns 41,471 shares of the company's stock worth $133,000 after buying an additional 9,464 shares during the last quarter. Barclays PLC raised its position in Organogenesis by 17.0% during the fourth quarter. Barclays PLC now owns 110,915 shares of the company's stock valued at $355,000 after purchasing an additional 16,106 shares in the last quarter. Mariner LLC purchased a new position in shares of Organogenesis in the fourth quarter worth about $123,000. Dimensional Fund Advisors LP grew its stake in shares of Organogenesis by 18.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,789,265 shares of the company's stock worth $8,925,000 after purchasing an additional 442,772 shares during the last quarter. Finally, MetLife Investment Management LLC boosted its position in Organogenesis by 34.9% during the 4th quarter. MetLife Investment Management LLC now owns 36,593 shares of the company's stock valued at $117,000 after acquiring an additional 9,465 shares in the last quarter. 49.57% of the stock is owned by institutional investors.

Organogenesis Stock Performance

Shares of NASDAQ:ORGO traded down $0.02 on Friday, hitting $5.02. 182,377 shares of the company's stock were exchanged, compared to its average volume of 1,397,364. The firm's 50-day moving average is $4.59 and its 200 day moving average is $4.21. The company has a market capitalization of $636.20 million, a PE ratio of -35.10 and a beta of 1.75. Organogenesis has a 1-year low of $2.45 and a 1-year high of $6.71.

Organogenesis (NASDAQ:ORGO - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.08). Organogenesis had a negative net margin of 1.92% and a negative return on equity of 0.37%. The company had revenue of $101.01 million for the quarter, compared to analyst estimates of $104.75 million. Organogenesis has set its FY 2025 guidance at EPS. On average, analysts anticipate that Organogenesis will post -0.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on ORGO shares. Cantor Fitzgerald boosted their target price on Organogenesis from $7.00 to $9.00 and gave the stock an "overweight" rating in a research report on Friday, August 8th. BTIG Research reaffirmed a "buy" rating on shares of Organogenesis in a research note on Tuesday, July 15th. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $7.50.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.